Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds ...

Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

The bioengineering company Ossium Health has created a new program that offers deep-frozen bone marrow from deceased organ ...

With FDA approval for imetelstat and solid financials, Geron shows great promise in MDS treatment. Read more on GERN stock ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were ...

Davis is able to focus on different numbers now. A linebacker, Davis ranks third on the team with 12 tackles. Last week, ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

Positive preliminary outcomes were reported for the first leukemia patient treated with Ossium Health's organ donor bone ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...